Evidence Hub

Tildrakizumab: short‐term efficacy and safety in real clinical practice

M. Galán-Gutiérrez, L. Rodriguez-Fernandez-Freire, R. Ruíz-Villaverde

International Journal of Dermatology, 2021

15 citations

Abstract

References 1 Ale IS, Maibacht HA. Diagnostic approach in allergic and irritant contact dermatitis. Expert Rev Clin Immunol 2010; 6: 291–310. https://doi.org/10.1586/eci.10.4 2 Mowad CM, Anderson B, Scheinman P, et al. Allergic contact dermatitis: patient management and education. J Am Acad Dermatol 2016; 74: 1043–1054. https://doi.org/10.1016/j.jaad. 2015.02.1144 3 Chou WS, Oh A, Klein WMP. Addressing health-related misinformation on social media. JAMA 2018; 320: 2417–2418. https://doi.org/10.1001/jama.2018.16865 4 DeBord LC, Patel V, Braun TL, et al. Social media in dermatology: clinical relevance, academic value, and trends across platforms. J Dermatolog Treat 2019; 30: 511–518. https:// doi.org/10.1080/09546634.2018.1530444 5 Voller LM, Kullberg SA, Liou YL, et al. Effectiveness of support groups for patients with contact dermatitis: a pilot study. Dermatitis 2020; 31: 383–388. https://doi.org/10.1097/DER. 0000000000000624

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free